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ABSTRACT 
Binding interactions between human serum albumin (HSA) and four approved 
epidermal growth factor receptor (EGFR) inhibitors gefitinib (GEF), erlotinib (ERL), afatinib 
(AFA), osimertinib (OSI), as well as the experimental drug KP2187 were investigated by 
means of spectrofluorometric and molecular modelling methods. Steady-state and time 
resolved spectrofluorometric techniques were carried out, including direct quenching of 
protein fluorescence and site marker displacement measurements. Proton dissociation 
processes and solvent dependent fluorescence properties were investigated as well. The EGFR 
inhibitors were predominantly presented in their single protonated form (HL
+
) at 
physiological pH except ERL, which is charge-neutral. Significant solvent dependent 
fluorescence properties were found for GEF, ERL and KP2187, namely their emission spectra 
show strong dependence on the polarity and the hydrogen bonding ability of the solvents.  
The inhibitors proved to be bound at site I of HSA (in subdomain IIA) in a weak-to-
moderate fashion (logK’ 3.9-4.9) using spectrofluorometry. OSI (logK’ 4.3) and KP2187 can 
additionally bind in site II (in subdomain IIIA), while GEF, ERL and AFA clearly show no 
interaction here. Docking methods qualitatively confirmed binding site preferences of 
compounds GEF and KP2187, and indicated that they probably bind to HSA in their neutral 
forms. Binding constants calculated on the basis of the various experimental data indicate a 
weak-to-moderate binding on HSA, only OSI exhibits somewhat higher affinity towards this 
protein. However, model calculations performed at physiological blood concentrations of 
HSA resulted in high (ca. 90%) bound fractions for the inhibitors, highlighting the importance 
of plasma protein binding.  
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1. Introduction 
Tyrosine kinases are important mediators of signalling cascades playing key roles in 
diverse biological processes such as cell growth, differentiation, proliferation, apoptosis and 
migration [1]. Since the beginning of this century, several tyrosine kinase inhibitors (TKI) 
have been approved for cancer treatment including the class of epidermal growth factor 
receptor (EGFR, also referred as erbB1, Her1) inhibitors. The EGFRs represent a subfamily 
of tyrosine kinases and the deregulation of this receptor network is well recognized as 
oncogenic driver of various cancer types [1,2]. Gefitinib (GEF, Iressa
®
) was the first selective 
inhibitor drug of the tyrosine kinase domain of EGFR approved in 2003 for the treatment of 
advanced or metastatic non-small-cell lung cancer (NSCLC) [3]. Similarly to GEF, Erlotinib 
(ERL, Tarceva
®
) is a reversible inhibitor of EGFR and binds at the ATP binding site of the 
receptor. It is utilised for the first-line treatment of EGFR-mutant NSCLC and pancreatic 
cancer [3]. Afatinib (AFA, Gilotrif
®
) containing an acrylamide reactive group was the first 
irreversible inhibitor of EGFR, which was approved by the FDA in 2013 with similar 
indications as the former two compounds [4]. Unfortunately, cancer patients frequently 
become resistant to these inhibitors, which initiated their further development. The third-
generation inhibitor osimertinib (OSI, Tagrisso
®
) has been specifically developed for EGFR-
gene mutated (T790M) cancers being resistant against the other EGFR inhibitors and was 
approved in 2017 [4]. EGFR inhibitors are orally administered drugs and enter systemic 
circulation via the bloodstream. Consequently, the impact of plasma protein binding is of high 
importance concerning drug distribution, elimination or drug efficacy [5]. Notably plasma 
half-lives of the EGFR inhibitors GEF, ERL and AFA in patients range from 36 to 48 h and 
extensive plasma protein binding (>90%) was reported [6-8], whereas for OSI only high 
plasma protein binding was assumed [9]. Thus, thorough investigation of the nature and 
primary binding sites on the plasma protein might represent an important issue for the 
understanding and comparison of the pharmacological activity and the pharmacokinetic 
behavior of these therapeutic agents. 
Human serum albumin (HSA) is the most abundant plasma protein with a concentration 
of ~630 μM [10]. This protein serves as a transport vehicle for a wide variety of endogenous 
compounds such as fatty acids, bilirubin, metal ions, but also for a variety of pharmaceutical 
compounds. HSA is a single chain globular protein comprising three structurally homologous 
domains (I, II and III), each consisting of two subdomains (A, B). The principal binding sites 
are located in the hydrophobic pockets in subdomains IIA and IIIA forming site I and II, 
respectively (according to Sudlow’s classification) [10,11]. A third binding pocket within 
subdomain IB (site III) has recently been identified which is considered as the third major 
binding site [12]. Besides HSA, alpha acid glycoprotein (AAG) has been identified as a potent 
binder of some TKIs including GEF and ERL [13-21]. At the same time its impact on the 
serum protein bound fraction of most TKIs was claimed to be insignificant compared to the 
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binding capacity of HSA that is present in 20–30-fold excess compared to AAG (20–30 μM) 
in the human blood [13]. Albumin binding of GEF, ERL and AFA was previously 
investigated by other research groups by means of spectrofluorometry, circular dicroism, 
NMR- and Fourier transform infrared spectroscopy, isothermal titration calorimetry, affinity 
chromatography and molecular modelling. The type of albumin used in these studies was not 
identical; some used bovine serum albumin (BSA) while others did HSA. Moreover, the 
location of the binding sites and calculated binding constants showed considerable variance 
depending mainly on the different (and sometimes questionable) methodological settings and 
experimental conditions [13-21]. For OSI a high affinity to HSA is merely assumed [9]. 
Therefore, we aimed to study the interaction of OSI and the experimental drug KP2187 
from our group (Chart 1) with HSA and to compare the data with the three approved EGFR 
inhibitors GEF, ERL and AFA to generate a data set with the same experimental conditions 
for all drugs. We included the experimental drug KP2187 as it exerts considerable 
antiproliferative activity and EGFR inhibitory effects on various cancer cell lines including 
ERL resistant H1975 cells [22]. Herein we report on an extensive comparative study of the 
EGFR inhibitors regarding their proton dissociation processes, fluorescence properties and 
their HSA binding affinities investigated by means of UV-Vis spectrophotometry and 
spectrofluorometric techniques. The experimental data are complemented by molecular 
modelling calculations. 
 
 
Chart 1. Chemical structures of the EGFR inhibitors investigated in this work. 
 
2. Materials and Methods 
2.1. Chemicals 
All solvents were of analytical grade and used without further purification. KCl, NaCl, 
HCl, KOH, dimethyl sulfoxide (DMSO), NaH2PO4 and Na2HPO4, warfarin (WF), 
gefitinib erlotinib afatinib
osimertinib KP2187
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dansylglycine (DG), HSA containing fatty acids (A8763) and fatty acid free (A1887) were 
purchased from Sigma Aldrich. Osimertinib (OSI) was purchased from Atomole Scientific, 
afatinib maleate (AFA-mal) from Chemscene, erlotinib (ERL) hydrochloride, gefitinib (GEF), 
and afatinib (AFA) free base from LC laboratories all in >98% purity. KP2187 [22] and 
dansyl sarcosine (DS) [23] were synthesized according to literature. Doubly distilled Milli-Q 
water was used for sample preparation. Samples for albumin binding studies were prepared in 
phosphate buffered saline (PBS) at pH 7.40. HSA solution and solutions of WF and DG were 
prepared as described previously [24,25]. Stock solution of DS was prepared on a weight-in-
volume basis and its molar absorbance was determined (328nm = 4397 M
−1
cm
−1
).This value 
was used to estimate the concentration of subsequent stock solutions. Slightly acidic stock 
solutions (c = 0.2‒1 mM; pH ~3) of the inhibitors were prepared and their concentrations and 
molar absorptivities were determined based on a weight-in-volume basis (see details in 
Section S1/Table S1). In HSA binding experiments these stocks were diluted with PBS to get 
our working solutions (c = 50‒200 μM, pH = 7.40). 
2.1. UV–Vis spectrophotometric, spectrofluorometric and pH-potentiometric studies: 
determination of pKa values and spectral characteristics in various solvents 
The pH-dependent titrations were performed over the pH range 2.0–11.5 at 25.0 ± 
0.1 °C and an ionic strength of 0.10 M (KCl) for keeping the activity coefficients constant. 
The titrations were performed with carbonate-free KOH solution (0.10 M) and its exact 
concentration was determined by pH-potentiometric titrations. Samples were degassed by 
bubbling purified argon through them for ~10 min prior to the measurements and was passed 
over the solutions during the titrations. The pH-potentiometric titration of KP2187 was 
performed according to the standard approach used in our previous works [26-28]. 
A Hewlett Packard 8452A diode array spectrophotometer was used to record the UV–
Vis spectra in the interval 200–800 nm. The path length (l) was 1 or 2 cm. The initial volume 
of the samples was 10.0 or 20.0 mL and the compound concentrations were 5, 10 or 50 µM.  
The pH-dependent fluorescence measurement for KP2187 was carried out on a Hitachi-
4500 spectrofluorometer at 10 μM concentration with an excitation wavelength (λEX) of 
370 nm. The emission spectra were recorded in a 1×1 cm quartz cell at 25.0 ± 0.1 °C.  
The proton dissociation constants and the UV–Vis or fluorescence emission spectra of 
the individual species in the various protonation states were calculated by deconvolution of 
the spectra recorded in the pH range from 2.0 to 11.5 with the computer program PSEQUAD 
[29]. The calculations were always made from the experimental titration data measured in the 
absence of any precipitate in the solution.  
Fluorescence and UV-Vis spectra were recorded in n-hexane, benzene, n-octanol, 
ethanol, methanol and water (at pH 7.40 and 11.0) at 1 or 5 μM compound concentration. 
Compounds were directly dissolved in the solvents or 10 mM stock solutions in methanol 
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were prepared and stepwise diluted with the appropriate solvent to obtain the desired 
concentration.  
 
2.2. Lipophilicity 
Distribution coefficient (D7.4) value of KP2187 was determined by the traditional 
shake-flask method in n-octanol/buffered aqueous solution at pH 7.40 (PBS) at 25.0 ± 0.2 °C 
as described previously [30]. The ligand was dissolved in n-octanol pre-saturated aqueous 
solution of the buffer at 50 M concentrations.  
 
2.3. Interaction with HSA 
2.3.1. Spectrofluorometric steady state measurements 
Fluorescence measurements were carried out on a Fluoromax-4P (Horiba Jobin Yvon) 
and on a Hitachi 4500 spectrofluorometer. Samples were measured in 1×1 cm cells at 37°C. 
All samples were prepared in PBS (pH 7.40) and were incubated for 1 h at 37 °C. 
Samples usually contained 1 μM HSA and various HSA-to-compound ratios (up to 1:30) were 
used. In the site marker displacement experiments, the HSA-to-site marker (WF, DG or DS) 
ratio was 1:1 and the concentration of the EGFR inhibitors was varied from 0 to 30 μM. In 
some cases the HSA–EGFR inhibitor (1:1) containing samples (cHSA = 1 or 10 μM) were 
titrated by site markers (up to 30 equivalents). The excitation wavelengths were 295, 310, 
340, 370 or 400 nm depending on the type of experiment and the emission intensity was 
collected in the range 310–650 nm (see Table S2 for details). The conditional binding 
constants were calculated with the computer program PSEQUAD [29] as described in our 
previous works [24,31]. Data presented are the mean value ± standard deviation of at least 
two independent assays.  
Job’s method was also used to estimate binding stoichiometry between HSA and ERL, 
GEF or KP2187. The total concentration was constant (10 μM) and the HSA-to-compound 
ratio was varied. 
3D spectra were recorded between 230–500 nm excitation and 250–550 nm emission 
wavelengths.  
Corrections for self-absorbance and inner filter effect were necessary in the steady-state 
fluorometric experiments since the emitted light was partly absorbed by the compounds. 
Corrections were carried out according to equation (1) [32], 
  𝐼𝑐𝑜𝑟𝑟 = 𝐼𝑚𝑒𝑎𝑠 × 10
(𝐴𝐸𝑋+𝐴𝐸𝑀) 2⁄   (1)  
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where Icorr and Imeas are the corrected and measured fluorescence intensities, AEX and AEM are 
the absorbance values at the excitation and emission wavelengths in the samples, respectively.  
 
2.3.2. Time-resolved fluorescence measurements 
Fluorescence lifetime for KP2187 was measured using a nanoLED N-370 (EM = 
440 nm) light source (Horiba Jobin Yvon) using FluoroHub-B time correlated single-photon 
counting (TCSPC) system. The resolution of the detection system was 50 ps. The number of 
counts on the peak channel was 10,000. The number of channels per curve used for the 
analysis was ~1,400 with a time scale of 0.05487 ns/channel. Ludox
®
 (from Sigma-Aldrich) 
was used as the scatter to obtain the instrumental response function. The background 
(obtained with the blank sample) was subtracted from the decay. The program DAS6 (version 
6.6.; Horiba, Jobin Yvon) was used for analysis of the experimental fluorescence decays. The 
fluorescence intensity decay over time is described by a sum of exponentials, 
𝐼(𝑡) = ∑ 𝛼𝑖
𝑛
𝑖=1 𝑒𝑥𝑝 (
−𝑡
𝜏𝑖
) (2) 
where i and i are the normalized amplitude and lifetime of component i respectively. 
From these parameters, the fraction of emitted light by each component i can be calculated 
through 
𝑓𝑖 =
𝛼𝑖𝜏𝑖
∑(𝛼𝑖𝜏𝑖)
  (3) 
The quality of the fit was judged from a 2R value close to 1.0 and a random distribution 
of weighted residuals. 
 
2.3.3. Ultrafiltration 
Ultrafiltration/UV-Vis measurements were performed with AFA, OSI and KP2187. 
Samples were prepared in PBS containing 50 µM compound. Two different types of Millipore 
filters were used for separation: Amicon Ultra-0.5 (cutoff: 10 kDa) and Centrifree 
Ultrafiltration Device (cutoff: 30 kDa). 0.5 or 1.0 mL portions were filtered with an 
Eppendorf MiniSpin plus centrifuge (relative centrifugal force ~8000 g, 5–10 min) and the 
UV-Vis spectrum of the filtrate (‘low molecular mass (LMM)’ fraction) was compared to the 
reference spectra of the original sample. 
 
2.4. Molecular docking 
 X-ray crystallographic structures of HSA in complex with WF (site I, PDB code: 
2BXD [33]) 3-carboxy-4-methyl-5-propyl-2-furanopropanoic acid (CMPF, site II, PDB code: 
8 
 
2BXA [33]) and 4Z,15E-bilirubin-IXα (bilirubin, site III, PDB code: 2VUE [34]) were used 
as docking targets, after missing amino acid side chains were reconstructed using the Swiss-
PDBViewer [35]. Amino acid side chains of HSA within 5 Å from any atom of the bound 
compounds in the crystal complexes were kept flexible as well as all ligand torsions to 
simulate 'induced fit' binding mechanism. All ligands were docked in both neutral and single 
protonated states. Non-polar hydrogens of ligands were merged with the connected carbon 
atoms. Fixed partial atomic charges were assigned using the Gasteiger method, preserving the 
net charge corresponding to the protonation state of the ligands. Re-docking of WF, CMPF 
and bilirubin for the validation of binding sites, as well as flexible docking of GEF and 
KP2187 to all three sites were performed using the Autodock 4.2 software and the 
Lamarckian genetic algorithm in a 80 Å x 80 Å x 80 Å grid volume with 0.375 Å grid point 
spacing. 1000 dockings were done for all compounds and protein binding sites. The resulting 
ligand-protein complexes were clustered to eliminate duplicate binding poses and then ranked 
according to their corresponding binding free energies. 
 
3. Results and discussion 
3.1. Proton dissociation processes and lipophilicity of the EGFR inhibitors 
The proton dissociation constants (pKa) of the approved EGFR inhibitors can be found 
in the ‘Product monographs’ of their pharmaceutical formulations on the homepages of the 
respective companies. [6-9]. However, these documentations often do not contain the 
measurement conditions such as solvent or the applied ionic strength. In addition, the data 
sometimes differ significantly. Therefore we measured pKa values of these EGFR inhibitors 
and KP2187 under the same experimental setup (I = 0.1 M KCl), to generate comparable data 
at physiologically relevant conditions. All calculated pKa values of the five different EGFR 
inhibitors are listed in Table 1. 
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Fig. 1. UV–Vis absorbance spectra of AFA recorded at various pH values. Inset shows the 
individual molar absorbance spectra of the inhibitor in different protonation states denoted as 
H2L
2+
, HL
+
 and L {clig = 5 μM; l = 2 cm; T = 25 °C; I = 0.10 M (KCl)}. 
 
Fig. 1 shows the UV-Vis absorbance spectra of AFA recorded in the pH range 2–11.5. 
The spectra change considerably between pH 4.0 and 6.5, which can be attributed to the 
deprotonation of the quinazolinium NH
+
. The second step is followed by smaller spectral 
changes due to the deprotonation of the terminal NMe2H
+
 moiety situated far from the 
chromophore moiety. Similar behavior was found for the other four inhibitors (except ERL 
that possesses only one dissociable proton in the studied pH range).  
The relatively good water solubility and fluorometric activity of KP2187 allowed us to 
determine its pKa values additionally by both pH-potentiometric and spectrofluorometric 
titrations. Emission spectra of KP2187 recorded at various pH values are shown in Fig. 2. The 
first deprotonation process (pH 4–7) resulted in a blue shifted emission maximum (456 nm 
(HL
+
) vs. 506 nm (HL
2+
)) and somewhat elevated intensity. On the other hand, the second 
proton dissociation step (pH 7–10) was accompanied by a red shift (λEM(max) 477 nm) and 
strongly increased emission intensities in contrast to the only slight alteration of the UV-Vis 
spectra in the same pH range (Fig. S1). Probably the formation of the charge neutral L species 
reduces the efficacy of non-radiative relaxation processes resulting in a high increase of the 
fluorescence signal [32]. The data obtained with pH-potentiometric and spectrofluorometric 
titrations are in good agreement with the results of the spectrophotometric titration (Table 1). 
 
 
Fig. 2. Fluorescence emission spectra of KP2187 measured at various pH values. Inset shows 
intensity changes at 477 nm {clig = 10 μM; EX = 370 nm; T = 25 °C}. 
 
It was found that the first pKa of the EGFR inhibitors bearing a quinazoline ring varies 
within 5.05 and 5.58, whereas the trend of the ligand basicities is: AFA < GEF < ERL < 
KP2187. In case of OSI pKa1 was previously attributed to the aniline-like nitrogen [9]. Instead 
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deprotonation of a pyrimidinium NH
+
 is more likely as the first step (Fig. S2) [36]. The 
second pKa is characteristic for aliphatic nitrogens, namely NMe2H
+
 in AFA and OSI, NH3
+
 in 
KP2187 and NmorpholineH
+
 in GEF. Calculated acidity constants are in reasonable agreement 
with data reported in literature (see Table 1). The knowledge of these dissociation constants 
allowed us to compute fractions for the actual protonation states at physiological pH (Table 
1). 
Lipophilicities of the approved inhibitors are already reported in the literature but not 
for KP2187. Table 1 comprises the measured and reported distribution coefficients (logD7.40) 
at pH 7.40. All compounds appear to be highly lipophilic, with a somewhat lower lipophilicity 
in case of KP2187.  
 
Table 1. Proton dissociation constants (pKa) of the studied inhibitors determined by UV-Vis 
spectrophotometry, calculated distribution (%) of the species in different protonation states at 
physiological pH (pH 7.40) and the distribution coefficients (logD7.40) at pH 7.40 {T = 25 C; 
I = 0.1 M (KCl)}.
 
 GEF ERL AFA KP2187 OSI 
pKa1 5.27 ± 0.02 
lit: 5.4 [6] 
5.38 ± 0.02 
lit: 5.6 [7] 
5.05 ± 0.03 
lit: 5.0 [8] 
5.58 ± 0.01 
5.56 ± 0.01b 
5.56 ± 0.01c 
4.74 ± 0.01 
lit: 4.4
 
 [9] 
pKa2 8.00 ± 0.05 
lit: 7.2 [6] 
- 8.80 ± 0.02 
lit: 8.2 [8] 
9.20 ± 0.06 
9.21 ± 0.01b 
9.21 ± 0.02c 
8.99 ± 0.05 
lit: 9.5 [9] 
Protonation states at pH 7.40 (%) 
H2L
2+
  - - - 1.5 - 
HL
+
  80 1 96 97 97 
L  20 99 4 1.5 3 
logD7.40 lit: 2.5
a
 lit: 2.9 [7] lit: 3.8 [8] 1.86 ± 0.03 lit: 3.4 [9] 
a
 Calculated from logP = 3.2 reported in Ref. [37] (logD = logP + log(molar fraction of L)). 
b
 Determined by spectrofluorometric titrations. 
c
 Determined by pH-potentiometric titrations.  
 
3.2. Fluorescence properties of the inhibitors 
The knowledge of the fluorescence properties of the studied EGFR inhibitors is 
essential as protein binding studies often use fluorescence based techniques. Consequently, 
solvent dependent fluorescence properties of the different EGFR inhibitors were investigated.  
11 
 
Among the five studied EGFR inhibitors only KP2187 exerts measurable fluorescence 
emission in aqueous solution as shown in Fig. 2. The four approved inhibitors displayed 
negligible fluorescence in aqueous solution at any protonation state. However, ERL and GEF 
were reported to be fluorescent in some non-aqueous solvents [38]. We measured the 
fluorescence properties of the inhibitors in the organic solvents such as n-hexane, benzene and 
n-octanol. The relative emission intensities and positions of λ(max) in the emission, excitation 
and absorption spectra are listed in Table 2.  
 
Table 2. Relative fluorescence intensities and (max) values of the emission, excitation 
and absorption spectra of ERL, GEF and KP2187 recorded in various solvents (T = 25 °C) 
and in the presence of HSA.  
 solvent relative 
intensity
a
 
λEM(max) 
(nm) 
λEX(max) 
(nm) 
λAbs(max) 
(nm) 
E
R
L
 
n-hexane 1.00 372 328, 340 332, 344 
benzene 0.38 423 334, 342 336, 346 
n-octanol 0.07 400–470b 337, 344 336, 346 
water pH 7.40 - - - 332 
HSA
c
 - 380–400b 336, 347 - 
G
E
F
 
n-hexane 1.00 368 330, 341 332, 344 
benzene 0.30 446 332, 342 332, 340 
n-octanol 0.08 390–450b 334, 343 334, 344 
water pH 11.0 
pH 7.40 
- 
- 
- 
- 
- 
- 
330 
330 
HSA
c
 - 378 334, 347 - 
K
P
2
1
8
7
 
n-hexane 0.002 416 370 - 
n-octanol 1.000 449 383 378 
ethanol 0.264 452 378 378 
methanol 0.226 452 378 378 
water pH 11.0 
pH 7.40 
0.019 
0.003 
477 
457 
366 
370 
368 
368 
 HSA
c
 - 441 372 - 
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a
 Compared to the most emissive form of each compound and calculated from the 
intensities measured at λEM(max) and λEX(max), 
b
 Broad plateau . 
c
 Recorded in the 
presence of 5 eq. HSA in aqueous solution at pH 7.40 (PBS) and at 37 °C. 
 
The emission maximum of ERL is shifted to higher wavelength and the peak intensity is 
lower in benzene compared to n-hexane (EM(max) = 423 nm and 372 nm, respectively). This 
red shift and intensity loss are even more pronounced in n-octanol (Table 2 and Fig. S3). The 
anomalous and broad emission band in n-octanol may indicate specific solvent-solute 
interaction(s) [32,39]. Fig. 3 represents large red shift of λEM(max) of ERL dissolved in n-
hexane upon addition of ca. 1% methanol or ethanol. Most probably interaction via hydrogen 
bonding occurs between ERL and the alcohols [39].While benzene causes only a gradual shift 
in λEM(max), corresponding to general solvent effect. The shape of the excitation spectra was 
rather similar in all solvent(s) or solvent mixture(s) displaying a doubled excitation peak in 
accordance with the absorbance spectra measured in the same solvents (Table 2 and Fig. S4).  
 
Fig. 3. Effect of solvent mixture composition on the emission maximum (max)) of ERL, 
dissolved in n-hexane with indicated amounts of methanol (♦), ethanol (■) or benzene (●) 
added. The dotted line depicts the gradual increase of the max) (R
2
 = 0.997, and the 
linearity remains up to 100% benzene content). Inset shows the spectral changes upon 
addition of methanol {clig = 1 μM; EX = 334 nm; T = 25 °C}. 
 
The same solvent dependent behavior and spectral characteristics were found for GEF 
(Table 2). The fluorescence of ERL and GEF in pure ethanol and methanol was negligible. 
Notably, our data in ethanol and n-hexane are in contrast to the observations of Trummer et 
al., where ERL and GEF proved to be moderately emissive in ethanol and weakly in n-
hexane. However, their spectra were recorded at 15-fold higher concentration compared to 
levels used in our studies and emission was not monitored below 390 nm [38] although we 
found the emission maxima in n-hexane at ~370 nm. 
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KP2187 displays considerably different fluorescence behavior compared to ERL and 
GEF. Specific effect of hydrogen bonding solvents was observed here as well (Table 2 and 
Fig. S5), but measured intensities revealed an unusual pattern. Relatively weak fluorescence 
observed in water (for the neutral form at pH 11) largely increases in alcohols, in the order of 
water << methanol < ethanol << n-octanol, but the compound exerts only a minimal 
fluorescence in n-hexane. This behavior is most probably due to an inversion of the electronic 
transition (n→π* vs. π→π*). Namely, in non-polar aprotic solvents relaxation is originated 
mainly from the n-π* state via radiationless processes, while emission occurs with high 
efficiency from the lowest excited state π-π* in hydrogen bonding solvents [39].  
Summarizing, the fluorescence properties of ERL, GEF and KP2187 proved to be 
primarily dependent on the hydrogen bonding ability and polarity of their environment. AFA 
and OSI were non-fluorescent in all types of media used above. These findings are important 
concerning the interpretation of the fluorescence spectra recorded in the presence of HSA. 
 
3.3. Albumin binding: fluorometric studies 
The reason for the choice of spectrofluorometric techniques to investigate the HSA 
binding of the selected EGFR inhibitors is their generally poor water solubility at pH 7.40. 
Ultrafiltration, a powerful tool to examine global binding events on a protein proved to be 
useless in our case, since even AFA and KP2187 (the two compounds with relatively good 
water solubility) stacked on the filter in 20–85% depending on the type of filter used. Often 
UV-Vis spectrophotometry is utilised to follow protein adduct formation processes. We also 
recorded such UV-Vis spectra of the inhibitors in the presence of HSA, which revealed weak 
but sometimes tendentious spectral alterations in some cases; while UV-Vis spectra recorded 
for the OSI–HSA system did not provide convincing evidence of any interaction (spectra 
shown for ERL–HSA and OSI–HSA systems in Fig. S6).  
 
3.3.1. Fluorometric studies via the intrinsic fluorescence of GEF, ERL and KP2187 
As described in Section 3.2 the inhibitors GEF, ERL and KP2187 were proved to be 
intrinsically fluorescent under certain conditions. Thus, the changes of their fluorescence 
properties were studied in the presence of HSA. First the binding kinetics of the interaction 
with HSA were investigated, the equilibria were reached within few minutes. Incubation time 
of 1 h was used for all samples. The 3D fluorescence spectra in Fig. 4 recorded for HSA 
and/or KP2187 depict the effect of HSA on the fluorescence of KP2187 and vice versa. It is 
clearly observable that the emission peak of HSA at λEM = 330 nm (that originates mainly 
from the tryptophan at position 214 (Trp
214
) near to site I in subdomain IIA) is slightly 
decreased in the presence of five equivalents of KP2187, which is a result of the binding of 
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this compound near to site I. On the other hand the emission intensity of KP2187 is increased 
up to ~10 fold in the presence of HSA.  
 
 
Fig. 4. 3D fluorescence spectra of (a) HSA, (b) KP2187 and (c) the HSA–KP2187 (1:5) 
system. Peak intensities and wavelength coordinates (I [λEX, λEM]) are indicated in the figure 
{cHSA = 1 µM; cKP2187 = 5 µM; T = 37 °C; pH = 7.40 (PBS); the spectra are corrected by self-
absorbance and inner filter effect}. 
 
These observations are a typical case of the (fluorescence) resonance energy transfer 
(often mentioned as FRET, or more correctly RET) phenomenon. The emission of the donor 
(HSA in our case) decreases while its electronic energy is transferred to the acceptor molecule 
(KP2187). The latter compound emits the excess energy as light (or its non-radiative 
relaxation can take place as well) [32,39]. Proper orientation and distance of the donor and 
acceptor and spectral overlap between the emission of the donor and absorption spectra of the 
acceptor moieties are required criteria of RET. The latter is fulfilled for the HSA–KP2187 
system (Fig. S7/a). And Fig. 4c provides a more convincing evidence for RET with the 
appearance of an extra ‘cross peak’ at λEX 280 nm/λEM 441 nm: the energy of the exciting 
light should be absorbed by HSA (at λEX 280 nm) than transferred to and emitted by KP2187 
(λEM 441 nm). The appearance of RET is considered as a proof for the binding of KP2187 on 
HSA nearby Trp
214
. Comparing the emission maximum of KP2187 in the presence of HSA 
(441 nm) to the values recorded in various solvents (Table 2) it can be seen that they are 
rather blue shifted compared to the aqueous or alcoholic solvents. Additionally, the intensity 
increased considerably in comparison with the aqueous solution at pH 7.40 (or even at pH 
11). These findings refer to the existence of at least one (mainly non-polar i.e. hydrophobic) 
binding site, where hydrogen bonding occurs between KP2187 and corresponding amino acid 
side chains (eg. with imidazole-, carboxylate-, hydroxyl groups). The protonation state of the 
bound KP2187 could not be determined based on its spectral characteristics, although binding 
in neutral form is probable under these conditions taking into consideration that HSA 
possesses binding pockets for mainly neutral or negatively charged compounds [10,40]. 
2214 [280,330]
110 [305,457]
87 [370,457]
2104 [280,330]
1060 [280,441]
972 [370,441]
1211 [310,441]
(a) (b) (c)
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Similarly to KP2187, ERL and GEF become highly fluorescent in the presence of HSA. 
Emission spectra of ERL and GEF show an irregular prolate shape similar to that recorded in 
n-octanol or in n-hexane/methanol mixtures (Figs. 3, S3). λEX(max) values fall between the 
maxima recorded in n-hexane and benzene denoting again hydrophobic binding pocket(s) 
which provide hydrogen bonding interaction(s). Kabir et al. came to the same conclusion by 
careful analysis of thermodynamic parameters derived from the GEF–HSA interactions [14]. 
Appearance of RET is highly probable in case of GEF and ERL: required spectral overlap is 
fulfilled (Fig. S7b) and 3D spectra imply the appearance of the ‘cross peaks’ (Fig S8; 
although they are not that well separated as in case of KP2187). Interestingly induced 
fluorescence of ERL and GEF upon binding to albumin was not reported previously, probable 
reasons are that (i) in some studies BSA was used that possesses a somewhat different 
structure compared to that of HSA [15,18,19], or (ii) incorrectly this fluorescence was 
attributed to HSA [14]. Corrections by the absorbance are strongly recommended also in case 
of 3D spectra (one example is represented in Fig. S8), otherwise non-corrected data can easily 
lead to false conclusions.  
In order to estimate the binding stoichiometry of the HSA adducts formed with ERL, 
GEF and KP2187 Job’s method was applied. Fairly uncertain results were obtained, which 
might be explained by the relatively weak binding affinity of the compounds towards HSA. 
Our model calculations proved the limited availability of Job plot in case of binding affinities 
where logK’ < 6 (see details in SI/Section S2 and Fig.S14). Another possibility in case of the 
fluorescent KP2187 was to measure fluorescence lifetime decays. Lifetime measurements 
might provide information not only about the number of emitting species with different 
lifetimes but also about their quantitative contribution to the measured steady-state 
fluorescence and potentially their quantity in a sample. KP2187 alone displayed a very short 
lifetime at pH 7.40, that could not been separated from the scattered light component (Fig. 5), 
it is under the detection limit of this technique (<50 ps). In contrast, in the KP2187–HSA 
system (Fig. 5) the fluorescence intensity decay can be described very well by a sum of three 
exponentials. The lifetime of free KP2187 (τ1 = 30 ps) was kept constant and the two further 
lifetimes were fitted, which were widely independent of the various KP2187-to-HSA ratios as 
shown in Fig. 6. Mean lifetime values are τ2 = 4.8 ± 0.4 ns and τ3 = 10.1 ± 0.1 ns for these 
species. Pre-exponentials (α values, relative amplitudes) holding quantitative information 
became fairly uncertain, since the relative amplitude of the τ1 component incorporates the 
scattered light as well. Thus, we could correlate only pre-exponentials of the HSA bound 
species to each other by calculating α’ values presented in Fig. 6, where α’2 = α2 / (α2 + α3) 
and α’3 + α’2 = 1. These α’ values (i.e. the ratio of the two HSA bound forms) seem to be 
independent of the various KP2187-to-HSA ratios. Namely the binding affinities of the two 
forms are within approximately one order of magnitude. In summary, lifetime measurements 
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revealed and confirmed: (i) binding of KP2187 to HSA and (ii) the plausible existence of two 
accessible binding sites (iii) whose binding affinities are similar to each other. 
  
 
Fig. 5. Intensity decay of the fluorescence emission of (a) HSA–KP2187 1:1 and (b) 1:10, (c) 
KP2187 alone and (d) only the scatter {cHSA = 10 (a) or 1 (b) μM; cKP2187 = 10 μM; λEX = 
370 nm; λEM = 440 nm; T = 37 °C; pH = 7.40 (PBS)}. Bottom: residuals plot for the fitting of 
each decay in the HSA containing systems with a sum of three exponentials (τ1 = 30 ps 
(fixed); τ2 = 4.8 ns; τ3 = 10.1 ns). 
 
Fig. 6. Fitted lifetime values τ2 and τ3 and normalized amplitudes α’2 and α’3 (where α’3 + 
α’2 = 1) at various KP2187-to-HSA ratios. τ1 = 30 ps was kept constant {cHSA = 1-10 µM, 
cKP2187 = 1-10 µM; EX = 370 nm; EM = 440 nm; T = 37 °C; pH = 7.40 (PBS)}. 
 
The effect of fatty acid free HSA on the fluorescence properties of KP2187 was 
investigated as well, and no considerable differences could be observed between the 
fluorescence spectra of KP2187 recorded at various ratios with both types of albumin. 
Unfortunately the LED light source (λEX = 370 nm) of the instrument could excite GEF 
and ERL only in their red edge excitation region. Poor quality of the preliminary decay curves 
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recorded for HSA‒ERL and HSA‒GEF samples hindered further detailed characterisation of 
these systems. 
 
3.3.2. Binding at site I and II: Trp quenching and site marker displacement studies  
Our studies revealed the binding of ERL, GEF and KP2187 on HSA, thus we aimed to 
explore the location of the binding sites and to gain information about the binding of the non-
fluorescent compounds AFA and OSI.  
First, binding at site I was investigated via Trp quenching studies. Following the 
selective excitation of Trp
214
 at 295 nm, the fluorescence emission intensity can be attenuated 
by the binding at (or in close proximity to) this amino acid, as briefly mentioned in Section 
3.3.1. Representative quenching curves and emission spectra are presented in Fig. 7 for AFA 
and GEF. The different ability to bind at site I is clearly seen in the inserted plot. GEF 
displays higher affinity towards this site compared to AFA. In case of GEF a new band is 
developed in line with the quenching of the Trp emission, indicating the existence of RET 
discussed in Section 3.3.1. Quenching via RET is also likely in case of AFA and OSI, but 
transferred energy can be eliminated only in a non-radiative manner. Intensities under 340 nm 
were used to compute binding constant of GEF, where the induced emission of GEF was 
negligible (similarly to ERL). The calculated binding (quenching) constants in Table 3 
indicate relatively weak binding (logK’ ~4.0) of the compounds at site I, which is ~100 µM 
expressed as dissociation constant (KD). Only OSI (logK’ ~4.9, KD ~ 12.6 µM) possesses 
somewhat higher affinity. Two constants are shown in Table 3 for AFA: the higher binding 
constant (logK’ 4.2) belongs to the maleate salt form implying the parallel binding of maleate 
on the same site.  
 
Fig. 7. Quenching of Trp
214
 fluorescence in HSA in the presence of (a) AFA and (b) GEF, 
grey dashed spectra denote the emission of the compounds alone. Inset shows the relative 
emission intensities at 340 nm for HSA–AFA (♦) and HSA–GEF (●) systems and for AFA (◊) 
and GEF (○) alone {cHSA = 1 μM; ccomp = 0–30 μM (AFA) and 0–20 μM (GEF) EX = 
295 nm; T = 37 °C; pH = 7.40 (PBS)}. 
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Quenching constants for site I were already reported in literature for GEF, ERL and 
AFA (Table 3). Our HSA–ERL data (logK’ 4.4) are in reasonably good agreement with the 
constant of Ye et al. with logK’ 4.29 determined in quenching experiments at 35 °C [17]. 
Similar data is reported for the binding of ERL on the related protein BSA by Liu et al., with 
logK’ 4.30 [19]. The reported constant for BSA-ERL of Rasoulzadeh et al. (logK’ 4.75) is 
somewhat higher; however the inner filter effect was not taken into account in their work 
[18]. In case of GEF logK’ 4.16 (30 °C) derived from corrected spectra agrees well with our 
data (logK’ 4.2) [14], while non-corrected intensities result in a somewhat overestimated 
constant of logK’ 4.69 (37 °C) [15]. The binding constant for the AFA-BSA system was 
measured by Alanazi et al. and reported a rather high value of logK’ 5.87 [20] compared to 
logK’ 3.89 in our measurements. All of the reported constants are determined graphically by 
the use of the log-log linearization method. 
 
Table 3. Conditional binding constants (logK’) of the compounds at binding sites I and II of 
HSA determined by spectrofluorometric measurements and HSA-bound quantities (%) 
calculated for the theoretical systems containing HSA at physiological concentration 
(630 µM) and 10 µM compound {pH = 7.40 (PBS); 37 °C}. 
 GEF ERL AFA KP2187 OSI 
Trp
214
 quenching (site I) 
literature data for 
HSA:
b 
literature data for 
BSA:
b
 
4.2 ± 0.1 
4.16 [14]
c
 
4.69 ,[15] 
4.4 ± 0.1 
4.29 [17]
d
 
4.75 [18]
d
 
4.30 [19]
d
 
4.36 [21]
f
  
3.9 ± 0.1a 
 
5.87 [20]
e
 
4.2 ± 0.1 4.9 ± 0.1 
WF displacement (site I) 4.0 ± 0.1 4.3 ± 0.1 4.3 ± 0.1g 4.3 ± 0.1 4.6 ± 0.1 
DG displacement (site II) n.m.
h
 n.m.
h
 n.m.
h
 binding
 i
 4.3 ± 0.1 
HSA bound fraction (%)
j
 89 92 83 > 92 98 
a
 logK’(quench) = 4.2 ± 0.1 measured for the maleate salt. b Calculated by log-log linearization 
method. 
c-f
 Measured at 30 °C (c), 35 °C (d), 36 °C (e), 25 °C (f). g Measured for the maleate salt. 
h
 No measurable displacement. 
i
 Not quantified. 
j
 Calculations based on the averaged binding 
constants measured at site I together with the binding constant at site II if applicable; potentially 
underestimated values. 
 
Additionally, binding affinity at site I was followed via WF displacement experiments. 
Emission bands originating from the HSA bound compounds ERL and GEF overlap with the 
bands of WF and HSA–WF, which made it difficult to follow the displacement reactions and 
to compute binding constants. Two different kinds of data treating approaches were utilised, 
see details in the caption of Fig. S9. Both approaches gave similar displacement constants for 
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the HSA–ERL adduct logK’ 4.27 ± 0.01 and 4.36 ± 0.01 respectively, and the average value is 
listed in Table 3. The same procedure was used for GEF. 
HSA bound KP2187 emits at somewhat higher wavelengths, thus emission intensities 
measured between 335–390 nm were suitable for calculations. It is noteworthy that lifetime 
measurements followed at the emission of KP2187 revealed static quenching of HSA bound 
KP2187 in the presence of WF confirming real competition at site I. Most probably this site 
binds the shorter lived component (τ2 = 4.8 ns, see Section 3.3.1) showing decreasing 
normalized amplitudes in the presence of elevating WF concentration. Computed 
displacement constants are in good agreement with those obtained in quenching studies 
(Table 3). 
Site markers DG and DS [41,42] were applied to follow binding at site II. Clearly, no 
displacement could be detected in the case of AFA, ERL and GEF neither for the use of DG 
or for DS. OSI displaced DG in a weak but significant manner from its binding site (see Table 
3). Competition between DG and KP2187 was detected as well (Fig. S10) however excessive 
spectral overlap hindered the calculation of any binding constant.  
In all, the structurally similar inhibitors GEF, ERL and AFA clearly show no binding at 
site II, while site I was proved to be relatively weak but unequivocal binder. Site I and site III 
are reported in the literature for both ERL and GEF as primary binding sites [14,15,17,19]. 
Possible binding at site III was not subject of our investigations, thus involvement of site III 
cannot be precluded. However, our lifetime data on KP2187 denote the presence of two 
binding sites which corresponds well with the steady-state results indicating binding at site I 
and II, thus additional binding at site III is not feasible. OSI, as representative of a different 
structural class however displays somewhat stronger (but still moderate) affinity to site I 
compared to the other inhibitors and even site II is involved in its binding event. To the best 
of our knowledge binding constants and locations on HSA for OSI and KP2187 are reported 
here as first. 
 
3.3.3. Model calculations on the HSA binding of the studied compounds 
Equilibrium model calculations were performed using the computed binding constants 
in order to predict the HSA bound fraction of the studied EGFR inhibitors in human serum. 
For lack of overall binding data, the average constant of quenching and WF displacement 
studies, representing affinity towards site I, and displacement constant for site II (applicable 
only for OSI) were used in the model containing physiological amount of HSA (630 μM) and 
10 μM compound. These type of calculations may provide potentially underestimated protein-
bound fractions, as further binding sites (over site I and II) may exist which were not taken 
into account in this work. Considerable HSA binding of these compounds is revealed in our 
calculations (89 and 92% for GEF and ERL, respectively; see Table 3), which is in reasonably 
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good agreement with data reported in pharmacokinetic studies for marketed compounds GEF 
and ERL indicating 90% and 95% binding to serum proteins, respectively [6,7]. The 
calculated 83% HSA bound AFA are in fairly good correspondence with literature data: in 
vitro studies reported 80% AFA bound to HSA [8]. No data are reported on plasma 
distribution of OSI, but a high binding level is assumed [9] in good correlation to the 98% 
HSA binding from our model calculations. 
In all, despite the weak-to-moderate binding affinities determined in the present study 
and in literature [14,17] for the investigated EGFR inhibitors, extensive HSA binding in blood 
plasma can be expected mainly due to the very high levels of HSA. 
 
3.4. Molecular docking 
Docking methods are generally designed to study pharmacologically relevant, high-
affinity protein-ligand (receptor-ligand) interactions (logK’ ~7–12; pico-, nanomolar affinities 
expressed in KD). The same docking calculations are readily applied for lower affinity 
interactions including binding towards high capacity binding sites on HSA. However, in the 
latter case the results are usually more qualitative than quantitative.  
The experimental compound KP2187 and one of the marketed drugs containing the N-
phenylquinazolin-4-amine moiety, namely GEF were chosen to study the binding preferences 
towards site I, II and III on HSA. (Notably, GEF was considered to display the closest 
structural similarity to KP2187 among GEF, ERL and AFA regarding the flexibility of the 
substituent at position 6 on the quinazoline ring in addition to their protonation states at pH 
7.4 and their lipophilic character.) The possible protonation state of the binding forms was 
also in scope of these investigations since the single protonated HL
+
 form of GEF and 
KP2187 is predominant at physiological pH in water (see Table 1) but binding at the highly 
apolar binding pockets may force a deprotonation to the charge neutral L
0
 form. Interestingly, 
most papers pay no attention to this topic and in their studies only charge-neutral forms are 
used for docking calculations [14-16,19].  
To confirm reliability of docking results dockings of well-known site markers were 
performed. Docked complexes of WF (site I marker), 3-carboxy-4-methyl-5-propyl-2-
furanopropanoic acid (CMPF, site II marker) and the endogenous ligand 4Z,15E-bilirubin-IXα 
(bilirubin, site III marker) were compared to the reported crystallographic structures [33,34]. 
Details are discussed in SI/Section S3. Binding poses of WF and CMPF in sites I and II of 
HSA, respectively, were sufficiently reproduced. Less accurate reproduction of the bilirubin 
binding pose at site III may be attributed to the fact that docking calculations are more reliable 
for small molecules with limited number of rotatable bonds, such as WF and CMPF. 
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The binding of the protonated (HL
+
) and charge neutral (L
0
) forms of GEF and KP2187 
to certain sites was studied in the next step. The drug binding site I of HSA is described as a 
continuous non-polar cavity with three hydrophobic sub-chambers and two polar patches 
formed at the bottom and at the entrance of the pocket. The former polar patch includes 
Tyr
150
, His
242
 and Arg
257
, while the latter consists of Lys
195
, Lys 
199
, Arg
218
 and Arg
222
. This 
fairly large, structurally resilient pocket was shown to bind ligands of various size and 
structure [12,33] and even compounds which have similar chemical structure could bind to 
this site in different relative orientations [43]. The pocket is positively charged; therefore 
interactions with anionic or partially negative moieties of ligands are favoured for binding. 
Protonated GEF and KP2187 were found to bind to this site in an orientation similar to that of 
WF (Figs. 8. and Fig. S13,S15a). The positively charged morpholine moiety of GEF and the 
primary amino group of KP2187 were positioned outside the pocket, in fair distance from the 
polar patches formed by the basic amino acid side chains. The morpholine group of neutral 
GEF was, however, found to form polar contacts with the Arg side chains of the above 
mentioned positive patch. KP2187 in neutral form was found to bind in a pose highly similar 
to that observed for the protonated form.  
Site II of HSA is smaller in volume than site I. It consists of one hydrophobic chamber 
and one main polar patch formed by Arg
410
, Tyr
411
 and Lys
414
 [33]. Similarly to site I, the 
entrance of this pocket is lined with positively charged residues. It is difficult to compare the 
docked complexes of GEF and KP2187 (Fig. S11) to that of CMPF (Fig. S15b), because these 
compounds differ in size and structure significantly from the site marker. Similarly to that 
observed in the case of site I-bound ligands, the positively charged groups of protonated GEF 
and KP2187 were positioned away from the Arg
410 
and Lys
414 
side chains in the low-energy 
docked complexes. Halogenated aromatic moieties of GEF and KP2187 were found to group 
with a hydrophobic cluster formed by Phe
403
, Leu
407
, Leu
430
, Val
433
 and Leu
453
. Neutral forms 
of both GEF and KP2187 were found to bind in similar poses. 
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Fig. 8. Low-energy docked complexes of GEF and KP2187 in protonated and neutral forms in 
binding site I. Non-polar hydrogen atoms are omitted for clarity. (For the 2D ligand 
interaction diagrams see Fig. S13.) 
 
Concerning site III the docking calculations revealed that GEF and KP2187 insert in the 
groove formed by the four helices covered by residues 110-119 (Figs. S12). Such deep 
insertion as observed for bilirubin in the crystallographic structure of the bilirubin-HSA 
complex [34] was not observed, however, this may be explained by the smaller size of these 
compounds. Ligands bound at site III were proposed to form polar interactions with Arg
117
 
and Arg
186
. Such interactions were present in the docked protonated KP2187, but not in case 
of GEF in its protonated form. The morpholine moiety of GEF and the amino group of 
KP2187 were found to be projected away from Arg
117
 and Arg
186
, similarly to that observed 
for protonated ligands at the other two binding sites. These groups inserted deeper into the 
binding pocket in case of neutral ligands, but only the amino group of KP2187 was engaged 
in polar interactions.  
 
Table 4. Binding free energies of the docked complexes of GEF and KP2187 with HSA. 
 G (site I) / G (site II) / G (site III) / 
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kcal mol
-1
 kcal mol
-1
 kcal mol
-1
 
GEF
+
 -8.26 -9.82 -7.77 
GEF
0
  -8.13 -7.87 -7.29 
KP2187
+
 -7.54 -10.03 -9.04 
KP2187
0
 -8.64  -8.22 -7.24 
 
Calculated binding free energies (Table 4) suggest that the neutral ligands have a slight 
preference for site I, which is in qualitative agreement with experimental observations. Data 
obtained for protonated ligands did not confirm this trend. This suggests that although these 
ligands were shown to be protonated in aqueous solutions at neutral pH, they may bind to 
HSA in their neutral forms. This is further corroborated by the abundance of basic amino acid 
side chains in the binding pockets of HSA, which would disturb binding of positively charged 
ligands. Accepting the assumption regarding the neutral protonation state of the binding 
compounds, one can see the significantly lower affinity of GEF and KP2187 towards site III 
compared to site I and site II. In the case of both KP2187 and GEF binding at site I seems to 
be preferred slightly over site II, which corresponds well to the experimental results with GEF 
but not with KP2187 (Table 4). This contradiction between experimental and in silico results 
suggest that binding may take place through a more complex, multi-step mechanism or is 
modulated by some experimental conditions, which not taken into account for the dockings 
and are yet to be revealed.  
 
4. Conclusions 
In this work, the binding interactions between HSA and four approved EGFR inhibitors 
(GEF, ERL, AFA and OSI) as well as the experimental inhibitor KP2187 were investigated 
by means of spectrofluorometric and molecular modeling techniques. The albumin binding 
ability of OSI and KP2187 was not studied previously, and literature data reported for the 
other three are often not comparable to each other as a cause of the different experimental 
setups used. Steady-state and time resolved measurements, as well as fluorescence quenching 
and site marker displacement experiments were carried out. Proton dissociation constants and 
solvent dependent fluorescence properties were also investigated in order to get more insight 
into the nature of HSA binding. 
According to the proton dissociation constants, the studied inhibitors were found 
predominantly in their single protonated (HL
+
) form at physiological pH except ERL that was 
neutral under these conditions. GEF, ERL and KP2187 display solvent-dependent 
fluorescence properties, where the detected emission was highly sensitive to the polarity and 
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the hydrogen bonding ability of the solvent. AFA and OSI were non-fluorescent at any 
applied condition. 
All of the studied EGFR inhibitors proved to be bound to HSA with weak-to-moderate 
strength. Fluorescence characteristics of GEF, ERL and KP2187 in the presence of HSA 
referred to the existence of mainly hydrophobic binding pockets providing hydrogen bonding 
groups in HSA. This finding is supported by the observed binding of these compounds at the 
hydrophobic pocket site I (logK’ 3.9–4.4). Furthermore, fluorescence lifetime measurements 
performed with KP2187 implied the existence of two binding sites, which was confirmed by 
steady-state displacement measurements at site II. OSI was also proved to be bind at site II 
(logK’ 4.3), while other compounds (GEF, ERL and AFA) clearly show no binding at this 
site. Calculated binding constants showed only moderate binding to HSA, although OSI has 
somewhat higher binding constants. Although docking methods are generally tailored to study 
pharmacologically relevant, high-affinity protein(receptor)-ligand interactions, our docking 
calculations could qualitatively confirm the binding site preferences of GEF and KP2187, and 
indicated that these ligands may bind to HSA in their neutral forms. At the same time model 
calculations using the binding constants and simulating physiological concentrations of HSA 
resulted in fairly high, ca. 90% bound fraction for the inhibitors. These results are in good 
agreement with reported plasma distribution values of the approved EGFR inhibitors and 
underline the role of plasma protein binding in the pharmacokinetic profile of OSI and 
KP2187 even if the binding constants determined are not high values. 
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